- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05713292
Pirfenidone in Adult Hospitalized Patients With COVID-19
February 3, 2023 updated by: Bin Cao, Capital Medical University
A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pirfenidone in Adult Hospitalized Patients With COVID-19.
This center intends to conduct a multicenter, randomized, placebo-controlled study to evaluate the effectiveness and safety of Nintedanib ethanesulfonate soft capsule in the treatment of pulmonary fibrosis in patients with moderate to severe COVID-19.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
168
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100029
- China-Japan Friendship Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subjects Age ≥ 18 Willing and able to provide written informed consent
- SARS-CoV-2 infection confirmed by PCR test/antigen dectection or positive serologies
- Time of illness onset ≥8 days
- Have findings consistent with interstitial lung disease found on CT scan
- Willing not use other investigational agents of anti-fibrosis
Exclusion Criteria:
- Pre-existing severe liver disease
- Pre-existing severe chronic kidney disease
- Pre-existing interstitial lung disease
- Pre-existing severe COPD or other structural lung disease
- Receiving invasive mechanical ventilation
- Currently Pregnant or Breast Feeding
- Poor baseline health conditoin
- Disability to complete lung function test
- Receiving pirfenidone wthin half-year
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Pirfenidone
Pirfenidone 200mg tid for first week; subsequently, 400mg tid for 2 months
|
Pirfenidone 200mg tid for first week; subsequently, 400mg tid for 2 months
|
PLACEBO_COMPARATOR: Placebo
Pirfenidone placebo 200mg tid for first week; subsequently, 400mg tid for 2 months
|
Pirfenidone placebo
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To investigate the effect of pirfenidone on fibrotic signs induced by COVID19 infection
Time Frame: 3 months
|
|
3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
distance walked in 6 Minutes (6MWD)
Time Frame: at the 3 months follow-up vist
|
the difference between intervention group and placebo group
|
at the 3 months follow-up vist
|
the EuroQol five-dimension five-level (EQ-5D-5L)
Time Frame: at the 3 months follow-up vist
|
the difference between intervention group and placebo group
|
at the 3 months follow-up vist
|
Medical Research Council (mMRC) dyspnoea scale
Time Frame: at the 3 months follow-up vist
|
the difference of mMRC score between intervention group and placebo group
|
at the 3 months follow-up vist
|
difference of forced vital capacity (FVC) between two groups
Time Frame: at the 3 months follow-up vist
|
the difference of actual and predicted value between intervention group and placebo group
|
at the 3 months follow-up vist
|
difference of total lung capacity (TLC) between two groups
Time Frame: at the 3 months follow-up vist
|
the difference of actual and predicted value between intervention group and placebo group
|
at the 3 months follow-up vist
|
difference of DLCO between two groups
Time Frame: at the 3 months follow-up vist
|
the difference of actual and predicted value between intervention group and placebo group
|
at the 3 months follow-up vist
|
incidence of adverse event
Time Frame: within 2 months after enrollment
|
the difference of adverse event frequency between intervention group and placebo group
|
within 2 months after enrollment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
December 30, 2022
Primary Completion (ANTICIPATED)
March 2, 2023
Study Completion (ANTICIPATED)
March 30, 2023
Study Registration Dates
First Submitted
January 1, 2023
First Submitted That Met QC Criteria
February 3, 2023
First Posted (ACTUAL)
February 6, 2023
Study Record Updates
Last Update Posted (ACTUAL)
February 6, 2023
Last Update Submitted That Met QC Criteria
February 3, 2023
Last Verified
February 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Coronavirus Infections
- Coronaviridae Infections
- Nidovirales Infections
- RNA Virus Infections
- Virus Diseases
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Pneumonia, Viral
- Pneumonia
- Lung Diseases
- COVID-19
- Physiological Effects of Drugs
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Antineoplastic Agents
- Pirfenidone
Other Study ID Numbers
- CAP-China Pirfenidone
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19 Pneumonia
-
Ministry of Health, KuwaitUnknownPneumonia, Viral | Moderate COVID-19 Pneumonia, Severe COVID-19 PneumoniaKuwait
-
Institute of Vaccines and Medical Biologicals,...National Institute of Hygiene and Epidemiology, Vietnam; Hanoi Medical University and other collaboratorsCompletedPneumonia, Viral | COVID-19 Vaccine | COVID-19 Disease | SARS PneumoniaVietnam
-
Mahidol UniversityThe Government Pharmaceutical OrganizationCompletedPneumonia, Viral | Covid-19 | SARS Pneumonia | Covid-19 VaccineThailand
-
Patrick RobinsonRecruitingCovid19 | COVID-19 Pneumonia | COVID-19 Respiratory Infection | COVID-19 Acute BronchitisUnited States
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
Fundacion Clinica Valle del LiliUniversidad Autonoma de OccidenteCompletedCOVID-19 Pneumonia | COVID-19 (Coronavirus Disease 2019)Colombia
-
Medical University of LodzRecruitingCOVID-19 | COVID-19 Pneumonia | COVID-19 Respiratory InfectionPoland
-
Texas Tech University Health Sciences Center, El...RecruitingPneumonia, Viral | COVID-19 Pneumonia | COVID-19 Respiratory InfectionUnited States
-
Administracion Nacional de Laboratorios e Institutos...RecruitingCovid19 | COVID-19 Pneumonia | COVID-19 Respiratory InfectionArgentina
-
Fondazione Policlinico Universitario Agostino Gemelli...CompletedCovid19 | COVID-19 Pneumonia | COVID-19 Respiratory InfectionItaly
Clinical Trials on Pirfenidone Oral Product
-
Universidad Autonoma de Nuevo LeonCompletedSecond-degree Burn
-
Instituto do Cancer do Estado de São PauloRecruitingHepatocellular Carcinoma | Liver CancerBrazil
-
UAS Labs LLCCompleted
-
St George's, University of LondonRecruitingChronic Kidney Diseases | Heart Failure With Reduced Ejection Fraction | Hyperkalemia | ACE Inhibitor Induced Hyperkalaemia | Mineralocorticoid Resistant HyperkalemiaUnited Kingdom
-
University Hospital, BordeauxCompleted
-
Brigham and Women's HospitalUnknownChronic Kidney Diseases | HyperkalemiaUnited States
-
Peking Union Medical College HospitalUnknown
-
Xenon Pharmaceuticals Inc.CompletedHealthy VolunteersUnited Kingdom
-
Duke UniversityVifor PharmaCompletedEnd Stage Renal Disease | HyperkalemiaUnited States
-
National Cheng Kung UniversityNational Cheng-Kung University Hospital; Ministry of Science and Technology...Recruiting